RE:RE:Accountability or lack of it?I don't think they have any intention of cutting costs until Q4. If you read the way they've positioned their statements on cash flow, it's cash flow positve by end of year. That means they can drastically slash in 6-8 months or so while bleeding out until that point and still meet their claim. I think they are hoping for a partnership that will allow for the continuation of oncology trials, and if not, they'll restructure the company, but not until using up all their resources and waiting until the very last second. Feels super risky right now. I hope they know what they're doing. So far, they haven't convinced me or the market they do.